Retatrutide Cost: The Two Published Prices We Found

Retatrutide is the most hyped molecule in this category and one of the hardest to price. We went looking for what it costs across every provider we cover that sells it. Six do. On August 12, 2026, two of them published a figure we could read off their own live pages.

That ratio is the most useful thing on this page, so it goes first.

The two published prices

Both were read directly off the seller's own live pages on August 12, 2026. Concierge MD LA lists "Retatrutide $399/month" alongside its compounded semaglutide and tirzepatide; Dr. Gillis Wellness Center lists retatrutide among its oral GLP therapies "Available Starting at $149".

Two figures are not a market rate, and we are not going to average them into one. They are also not comparable to each other: one is an injection quoted as a monthly plan, the other an oral product quoted as a starting price, and a starting price is a floor rather than a rate. If you see a "typical retatrutide cost" quoted anywhere as a single number, ask how many sellers it was built from.

What the other four do

One lists retatrutide as a product — branded "RTT (GLP-3)" — without a price in anything a reader can see without starting an intake. Three sell it with no published figure at all: the price arrives at checkout, after a dose is selected, or after a consultation.

That is a much higher rate of price-gating than we see on compounded semaglutide or tirzepatide, where most sellers publish something. The pattern is worth naming rather than shrugging at: the least-established molecule is also the least-priced one in public.

Why the price is not the first question

Retatrutide is not approved by the FDA for anything. It is an investigational triple agonist — GIP, GLP-1 and glucagon — that produced substantial weight loss over 48 weeks in phase 2¹, and in 2026 its main phase 3 trials reported too: in TRIUMPH-1, average weight loss over 80 weeks was 25.0% on the 12 mg dose³. Trial results are not approval, and they are not a license to sell. Eli Lilly plans to submit its application to the FDA in the first quarter of 2027⁴, and it has not set a price; its own FAQ says only that pricing will come after the regulatory review⁶. Our guide to when retatrutide could be approved covers the timeline.

So anything you are quoted a price for today is a compounded or research-grade preparation of a drug no regulator has cleared, from a supply chain with no approved reference product to be measured against. The FDA says retatrutide cannot be used in compounding under federal law at all⁵. Our retatrutide dosage and retatrutide side effects pages set out what is actually known, and the evidence review for athletes and body recomposition covers what the trials do and do not show.

It is also banned in tested sport — see the WADA prohibited list — and if you are buying it as a research chemical rather than through a clinic, where to buy peptides and the legality problem is the page to read first.

What to check before you compare any two quotes

What does the figure buy? A month, four weeks, a vial, or a "starting" dose that rises. The four-week month is common enough in this category that we now check it on every provider.

Is it a plan or a floor? "Starting at" is a floor. It tells you the cheapest rung, not what you will pay at a working dose.

What do you pay after the first month? A single number on a poster can be an introductory rate with the ongoing price left off. SkinnyRx leads with a $99 first month for its injections and publishes no price for month two or later, so you cannot compare it with a seller that prints an ongoing rate until you have finished its intake. Ask for the month-two figure before you compare.

Who compounds it, and can you check? With no approved product to compare against, the pharmacy is most of what you are trusting. How to verify a COA is the practical check.

Do the milligrams and the syringe units agree? The FDA has warned specifically about dosing errors on compounded GLP-1s, where the vial is labeled in milligrams and the syringe reads in units². That risk does not shrink on a molecule with less prescribing experience behind it.

The honest takeaway: of six sellers we checked, two publish a retatrutide price — $399 a month for an injection and from $149 for an oral product — and neither is a market rate. The wider fact is more useful than either figure: the least-established molecule in this category is also the one whose price is hardest to see before you commit, and it is not approved for anything.